340 related articles for article (PubMed ID: 22070215)
1. A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis.
Fitzpatrick C; Floyd K
Pharmacoeconomics; 2012 Jan; 30(1):63-80. PubMed ID: 22070215
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of treating multidrug-resistant tuberculosis.
Resch SC; Salomon JA; Murray M; Weinstein MC
PLoS Med; 2006 Jul; 3(7):e241. PubMed ID: 16796403
[TBL] [Abstract][Full Text] [Related]
3. Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries.
Lu X; Smare C; Kambili C; El Khoury AC; Wolfson LJ
BMC Health Serv Res; 2017 Jan; 17(1):87. PubMed ID: 28122562
[TBL] [Abstract][Full Text] [Related]
4. Cost and cost-effectiveness of multidrug-resistant tuberculosis treatment in Estonia and Russia.
Floyd K; Hutubessy R; Kliiman K; Centis R; Khurieva N; Jakobowiak W; Danilovits M; Peremitin G; Keshavjee S; Migliori GB
Eur Respir J; 2012 Jul; 40(1):133-42. PubMed ID: 22362862
[TBL] [Abstract][Full Text] [Related]
5. Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review.
Laurence YV; Griffiths UK; Vassall A
Pharmacoeconomics; 2015 Sep; 33(9):939-55. PubMed ID: 25939501
[TBL] [Abstract][Full Text] [Related]
6. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of treating multidrug-resistant tuberculosis in treatment initiative centers and treatment follow-up centers in Ethiopia.
Alemayehu S; Yigezu A; Hailemariam D; Hailu A
PLoS One; 2020; 15(7):e0235820. PubMed ID: 32716915
[TBL] [Abstract][Full Text] [Related]
8. The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa.
Mpobela Agnarson A; Williams A; Kambili C; Mattson G; Metz L
Expert Rev Anti Infect Ther; 2020 May; 18(5):475-483. PubMed ID: 32186925
[No Abstract] [Full Text] [Related]
9. Cost effectiveness of decentralised care model for managing MDR-TB in India.
John D; Chatterjee P; Murthy S; Bhat R; Musa BM
Indian J Tuberc; 2018 Jul; 65(3):208-217. PubMed ID: 29933862
[TBL] [Abstract][Full Text] [Related]
10. Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria.
Bada FO; Blok N; Okpokoro E; Dutt S; Akolo C; Dakum P; Abimiku A
PLoS One; 2020; 15(12):e0241065. PubMed ID: 33259492
[TBL] [Abstract][Full Text] [Related]
11. Modeling the patient and health system impacts of alternative xpert® MTB/RIF algorithms for the diagnosis of pulmonary tuberculosis in Addis Ababa, Ethiopia.
Tesfaye A; Fiseha D; Assefa D; Klinkenberg E; Balanco S; Langley I
BMC Infect Dis; 2017 May; 17(1):318. PubMed ID: 28464797
[TBL] [Abstract][Full Text] [Related]
12. Impact of adverse drug reactions on the incremental cost-effectiveness of bedaquiline for drug-resistant tuberculosis.
Schnippel K; Firnhaber C; Page-Shipp L; Sinanovic E
Int J Tuberc Lung Dis; 2018 Aug; 22(8):918-925. PubMed ID: 29991402
[TBL] [Abstract][Full Text] [Related]
13. Cost-consequence analysis of ambulatory clinic- and home-based multidrug-resistant tuberculosis management models in Eswatini.
Peresu E; De Graeve D; Heunis JC; Kigozi NG
PLoS One; 2024; 19(4):e0301507. PubMed ID: 38564589
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
Wirth D; Dass R; Hettle R
BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of a decentralized care model for managing multi-drug-resistant tuberculosis in low- and middle-income countries: a systematic review protocol.
Mahapatra B; Bhattacharya P; Karuveettil V; John D; Khatoon S; Mukherjee N; Jankiram C
JBI Evid Synth; 2024 Jan; 22(1):97-105. PubMed ID: 37779435
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness of treating multi-drug resistant tuberculosis by adding Deltyba™ to background regimens in Germany.
Diel R; Hittel N; Schaberg T
Respir Med; 2015 May; 109(5):632-41. PubMed ID: 25862597
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of treating multidrug- and extensively drug-resistant tuberculosis: A systematic review.
Vo NX; Thuy Nguyen TT; Phuong Thao NT; Thanh Ho HP; Vo TQ
J Pak Med Assoc; 2019 Jun; 69(Suppl 2)(6):S131-S136. PubMed ID: 31369543
[TBL] [Abstract][Full Text] [Related]
18. Cost of multi drug resistance tuberculosis in Germany.
Diel R; Nienhaus A; Lampenius N; Rüsch-Gerdes S; Richter E
Respir Med; 2014 Nov; 108(11):1677-87. PubMed ID: 25443398
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of interventions for tuberculosis control: DALYs versus QALYs.
Diel R; Lampenius N
Pharmacoeconomics; 2014 Jul; 32(7):617-26. PubMed ID: 24849396
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]